On May 27, 2026, the American Cancer Society (ACS) officially incorporated Guardant Health’s Shield blood test into its national colorectal cancer screening recommendations. The move follows the U.S. Food and Drug Administration’s 2024 approval of the test and marks the first time a blood‑based screening option has been endorsed by the ACS for this disease. Colorectal cancer remains one of the United States’ most prevalent malignancies, with more than 150,000 new diagnoses reported each year.
Traditional screening methods have centered on colonoscopy and stool‑based tests. Colonoscopy, while highly effective, requires bowel preparation, sedation and often a day off work, while stool tests involve at‑home sample collection and mailing.
These logistical hurdles have contributed to a substantial portion of the population forgoing screening altogether. Guardant Health’s Shield test simplifies the process to a single blood draw. By detecting DNA mutations associated with colorectal cancer circulating in the bloodstream, the test eliminates the need for bowel prep, endoscopic equipment, or sample shipping.
For individuals who have avoided previous screening options, the reduced procedural burden could encourage greater participation. Dr. Karen Knudsen, chief executive officer of the ACS, described the guideline update as a “major step forward in the effort to eliminate cancer.” The ACS, a nationwide nonprofit that publishes leading journals such as *Cancer*, *CA: A Cancer Journal for Clinicians*, and *Cancer Cytopathology*, wields significant influence over clinical practice and insurance coverage decisions.
Its endorsement signals that the evidence supporting Shield meets the organization’s standards for effectiveness and safety. Early detection is critical: tumors identified at an early stage are linked to markedly better treatment outcomes, whereas late‑stage diagnoses correspond with poorer survival rates. By offering a low‑barrier screening tool that can be administered during routine medical visits, the Shield test aims to capture cancers that might otherwise be missed. The timing aligns with broader national priorities.
The current administration has repeatedly emphasized investment in cancer research and expanding access to life‑saving therapies. The ACS’s backing of a blood‑based test complements these policy goals, adding a concrete option to the national cancer‑control toolkit.
Medical professionals have monitored the development of blood‑based cancer screening for years, recognizing that colorectal tumors uniquely shed detectable DNA into the blood. The FDA’s 2024 clearance cleared the regulatory hurdle, while the ACS guideline now opens the professional pathway for widespread clinical use. Experts caution that the Shield test does not replace colonoscopy, which remains the gold standard for detecting and removing precancerous polyps in a single procedure.
Instead, Shield is positioned to identify existing cancers, expanding overall screening coverage. “A test that gets more people screened at all is better than a perfect test that nobody takes,” a specialist noted, underscoring the public‑health calculus.
Screening rates have yet to rebound to pre‑COVID‑19 levels, as the pandemic disrupted routine care and left many individuals without recent colonoscopies. The addition of a blood‑based option provides an alternative route for those who missed or delayed earlier appointments. Implementation will depend on insurance reimbursement, physician adoption, and patient acceptance.
While the guideline does not guarantee coverage, it serves as a strong endorsement from the nation’s largest cancer‑focused organization, indicating that the test is ready for integration into standard practice. With annual incidence exceeding 150,000 cases and thousands of preventable deaths each year, expanding accessible screening tools like Guardant Health’s Shield blood test could play a pivotal role in reducing the burden of colorectal cancer across the United States.
